Skip to main content
Premium Trial:

Request an Annual Quote

Applied Precision Makes Ownership Changes, Posts New CEO

NEW YORK, Feb. 1 - Boston investment firm Riverside Partners has taken a "significant" minority ownership position in Applied Precision and will post three representatives to a new nine-member management board, the company said in a statement today.

 

Under the new organization, company co-founder Ron Seubert, an electronic engineer, becomes CEO and a board member. The company's other two founders, Don Snow and John Stewart, will also sit on the new management board, but will be less involved in daily operations of the company; Snow will work half-time, and Stewart has retired.

 

The board will also include three industry experts from pharma, life sciences and semiconductors.

 

In addition, Applied Precision has reformulated as an LLC.

 

Riverside representatives will not directly manage the company, but will assist in strategic alliances for development, distribution and investment.

 

The investment firm's new stake in Applied Precision was not disclosed.

 

The Issaquah, Wash., company develops tools for measurement and analysis in biotech, communications and computing, including a biochip reader and live-cell microscopy systems.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.